Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme
- PMID: 9748545
- DOI: 10.1016/s0167-4781(98)00132-8
Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme
Abstract
Topoisomerase II is a ubiquitous enzyme that is essential for the survival of all eukaryotic organisms and plays critical roles in virtually every aspect of DNA metabolism. The enzyme unknots and untangles DNA by passing an intact helix through a transient double-stranded break that it generates in a separate helix. Beyond its physiological functions, topoisomerase II is the target for some of the most active and widely prescribed anticancer drugs currently utilized for the treatment of human cancers. These drugs act in an insidious fashion and kill cells by increasing levels of covalent topoisomerase II-cleaved DNA complexes that are normally fleeting intermediates in the catalytic cycle of the enzyme. Over the past several years, we have made considerable strides in our understanding of the catalytic mechanism of topoisomerase II and the mechanism of action of drugs targeted to this enzyme. These advances have provided novel insights into the physiological functions of topoisomerase II and have led to the development of more efficacious chemotherapeutic regimens and novel anticancer drugs. Considering the importance of topoisomerase II to the eukaryotic cell and to cancer chemotherapy, it is essential to understand its enzymatic function and pharmacological properties. Therefore, this review will discuss the mechanism of action of eukaryotic topoisomerase II and topoisomerase II-targeted drugs.
Similar articles
-
Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice.Prog Nucleic Acid Res Mol Biol. 2000;64:221-53. doi: 10.1016/s0079-6603(00)64006-0. Prog Nucleic Acid Res Mol Biol. 2000. PMID: 10697411 Review.
-
Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes.Curr Top Med Chem. 2003;3(3):321-38. doi: 10.2174/1568026033452519. Curr Top Med Chem. 2003. PMID: 12570766 Review.
-
Catalytic function of DNA topoisomerase II.Bioessays. 1991 Jun;13(6):269-73. doi: 10.1002/bies.950130603. Bioessays. 1991. PMID: 1654050 Review.
-
The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing.Nucleic Acids Res. 2009 Feb;37(3):738-48. doi: 10.1093/nar/gkn937. Epub 2008 Nov 28. Nucleic Acids Res. 2009. PMID: 19042970 Free PMC article. Review.
-
Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents. 2005 Jul;5(4):363-72. doi: 10.2174/1568011054222364. Curr Med Chem Anticancer Agents. 2005. PMID: 16101488 Review.
Cited by
-
Sublethal doses of β-amyloid peptide abrogate DNA-dependent protein kinase activity.J Biol Chem. 2012 Jan 20;287(4):2618-31. doi: 10.1074/jbc.M111.276550. Epub 2011 Dec 2. J Biol Chem. 2012. PMID: 22139836 Free PMC article.
-
Antitrypanosomal activity of fluoroquinolones.Antimicrob Agents Chemother. 1999 Aug;43(8):2066-8. doi: 10.1128/AAC.43.8.2066. Antimicrob Agents Chemother. 1999. PMID: 10428939 Free PMC article.
-
Differential regulation of NF-kappaB activation and function by topoisomerase II inhibitors.BMC Cancer. 2006 Apr 21;6:101. doi: 10.1186/1471-2407-6-101. BMC Cancer. 2006. PMID: 16630341 Free PMC article.
-
Preferential induction of MLL(Mixed Lineage Leukemia) rearrangements in human lymphocyte cultures treated with etoposide.Genet Mol Biol. 2009 Jan;32(1):144-50. doi: 10.1590/S1415-47572009000100022. Epub 2009 Mar 1. Genet Mol Biol. 2009. PMID: 21637660 Free PMC article.
-
Synthesis of 3,3'-methylenebis(4-hydroxyquinolin-2(1H)-ones) of prospective anti-COVID-19 drugs.Mol Divers. 2021 Feb;25(1):461-471. doi: 10.1007/s11030-020-10140-z. Epub 2020 Sep 14. Mol Divers. 2021. PMID: 32926254 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous